Ciprofloxacin bone infections

Bone infections in patients with a history of intravenous drug abuse require coverage for gram-negative organisms therefore, empirical treatment with ceftazidime 2 g intravenously every 8 hours plus an aminoglycoside is indicated. If compliance can be ensured, these patients are excellent candidates to receive oral ciprofloxacin 750 mg twice daily. Antibiotic therapy in these patients should be continued for at least 4 to 6 weeks. 

M fortuitum Abscess, sinus tract, ulcer bone, joint, tendon infection Amikacin, cefoxitin, ciprofloxacin, doxycycline, ofloxacin, trimethoprimsulfamethoxazole... 

Ciprofloxacin is approved for use in the treatment of bone and joint infections, infectious diarrhea caused by Shigella or Campylobacter, lower respiratory tract infections, skin infections, and urinary tract infections. It is the drug of choice for the treatment of infections caused by Campylobacter jejuni. In addition, it has found off-label use as an alternative drug for the treatment of gonorrhea, salmonella, and yersinia... 

Ciprofloxacin is a fluoroquinolone antibiotic that interferes with microbial DNA synthesis. It is indicated in the treatment of infections of the lower respiratory tract, skin and skin structure, bones and joints, urinary tract gonorrhea, chancroid, and infectious diarrhea caused by susceptible strains of specific organisms typhoid fever uncomplicated cervical and urethral gonorrhea women with acute uncomplicated cystitis acute sinusitis nosocomial pneumonia chronic bacterial prostatitis complicated intra-abdominal infections reduction of incidence or progression of inhalational anthrax following exposure to aerosolized Bacillus anthracis. Cipro IV Used for empirical therapy for febrile neutropenic patients. 

ABSORPTION, FATE, AND EXCRETION The quinolones are weU absorbed after oral administration and are widely distributed. Peak serum levels of the fluoroquinolones occur within 1-3 hours of an oral dose of 400 mg. Relatively low serum levels are reached with norfloxacin and limit its usefulness to the treatment of urinary tract infections. Food does not impair oral absorption but may delay the time to peak serum concentrations. Oral doses in adults are 200-400 mg every 12 hours for ofloxacin, 400 mg every 12 hours for norfloxacin and pefloxacin, and 250-750 mg every 12 hours for ciprofloxacin. Bioavailabrlity of the fluoroquinolones exceeds 50% for all agents and 95% for several. The serum half-lives range from 3 to 5 hours for norfloxacin and ciprofloxacin to 20 hours for sparfloxacin. The volume of distribution of quinolones is high, with concentrations in urine, kidney, lung and prostate tissue, stool, bUe, and macrophages and neutrophils higher than serum levels. Quinolone concentrations in CSF, bone, and prostatic fluid are lower than in serum. Pefloxacin and ofloxacin levels in ascites fluid approach serum levels, and ciprofloxacin, ofloxacin, and pefloxacin have been detected in human breast milk. 

---